questionId int64 337 21.2k | question stringlengths 11 168 | ucsf_document_page_no stringlengths 1 3 | answers list | question_types list | ucsf_document_id stringlengths 8 8 | data_split stringclasses 1
value | docId int64 279 6.32k | image unknown | ground_truth stringlengths 64 1.69k |
|---|---|---|---|---|---|---|---|---|---|
1,266 | What is the graphical representation about? | 2 | [
"Summary of Segment Attractiveness"
] | [
"layout"
] | xqjf0226 | train | 558 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOydbXarug6G39x15iVlZBIjsxiZ7w9/gyGk7W7SVs86h02wLcuEBiHL4hbhOI7jOI7zHvzv1Qo4juM4juMU3DBxHMdxHOdtcMPEcRzHcZy3wQ0Tx3Ecx3HeBjdMHMdxHMd5G9wwcRzHcRznbXDDxHEcx3Gct8ENE8dxHMdx3gY3TBzHcRzHeRvcMHEcx3Ec521ww8RxHMdxnLfBDRPHcRzHcd4GN0wcx3Ecx3kb3DBxHMdxHOdtcMPEcRzHcZy3wQ0Tx3E... | {"gt_parses": [{"question" : "What is the graphical representation about?", "answer" : "Summary of Segment Attractiveness"}]} |
1,267 | On what basis, the Summary of Segment Attractiveness is carried out? | 2 | [
"based on current situation & future trends",
"Based on current situation & future trends.",
"current situation & future trends"
] | [
"layout"
] | xqjf0226 | train | 558 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOydbXarug6G39x15iVlZBIjsxiZ7w9/gyGk7W7SVs86h02wLcuEBiHL4hbhOI7jOI7zHvzv1Qo4juM4juMU3DBxHMdxHOdtcMPEcRzHcZy3wQ0Tx3Ecx3HeBjdMHMdxHMd5G9wwcRzHcRznbXDDxHEcx3Gct8ENE8dxHMdx3gY3TBzHcRzHeRvcMHEcx3Ec521ww8RxHMdxnLfBDRPHcRzHcd4GN0wcx3Ecx3kb3DBxHMdxHOdtcMPEcRzHcZy3wQ0Tx3E... | {"gt_parses": [{"question" : "On what basis, the Summary of Segment Attractiveness is carried out?", "answer" : "based on current situation & future trends"}, {"question" : "On what basis, the Summary of Segment Attractiveness is carried out?", "answer" : "Based on current situation & future trends."}, {"question" : "O... |
1,268 | What are the three segments indicated in the graph? | 2 | [
"Treatment Machines, Life Negotiators, Struggle for Control"
] | [
"layout"
] | xqjf0226 | train | 558 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOydbXarug6G39x15iVlZBIjsxiZ7w9/gyGk7W7SVs86h02wLcuEBiHL4hbhOI7jOI7zHvzv1Qo4juM4juMU3DBxHMdxHOdtcMPEcRzHcZy3wQ0Tx3Ecx3HeBjdMHMdxHMd5G9wwcRzHcRznbXDDxHEcx3Gct8ENE8dxHMdx3gY3TBzHcRzHeRvcMHEcx3Ec521ww8RxHMdxnLfBDRPHcRzHcd4GN0wcx3Ecx3kb3DBxHMdxHOdtcMPEcRzHcZy3wQ0Tx3E... | {"gt_parses": [{"question" : "What are the three segments indicated in the graph?", "answer" : "Treatment Machines, Life Negotiators, Struggle for Control"}]} |
1,269 | what is the "document storage period " article number? | 3 | [
"7",
"Article 7"
] | [
"layout"
] | jpjf0226 | train | 556 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOydbXbrLK+G75z1zkt0ZCIjEx6Zzg9JgB2nO+3TOHGra62d3cR8COwgJAS5KJIkSZLkPfm/VwuQJEmSJPdIJZUkSZK8LamkkiRJkrcllVSSJEnytqSSSpIkSd6WVFJJkiTJ25JKKkmSJHlbUkklSZIkb0sqqSRJkuRtSSWVJEmSvC2ppJIkSZK3JZVUkiRJ8rakkkqSJEnellRSSZIkyduSSipJkiR5W1JJJUmSJG9LKqkkSZLkbUkllSRJkrwtqaSSJEm... | {"gt_parses": [{"question" : "what is the "document storage period " article number?", "answer" : "7"}, {"question" : "what is the "document storage period " article number?", "answer" : "Article 7"}]} |
1,270 | What is the conclusion obtained from the graph? | 2 | [
"All 3 segments have consistent needs",
"All 3 Segments Have Consistent Needs."
] | [
"layout"
] | xqjf0226 | train | 558 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOydbXarug6G39x15iVlZBIjsxiZ7w9/gyGk7W7SVs86h02wLcuEBiHL4hbhOI7jOI7zHvzv1Qo4juM4juMU3DBxHMdxHOdtcMPEcRzHcZy3wQ0Tx3Ecx3HeBjdMHMdxHMd5G9wwcRzHcRznbXDDxHEcx3Gct8ENE8dxHMdx3gY3TBzHcRzHeRvcMHEcx3Ec521ww8RxHMdxnLfBDRPHcRzHcd4GN0wcx3Ecx3kb3DBxHMdxHOdtcMPEcRzHcZy3wQ0Tx3E... | {"gt_parses": [{"question" : "What is the conclusion obtained from the graph?", "answer" : "All 3 segments have consistent needs"}, {"question" : "What is the conclusion obtained from the graph?", "answer" : "All 3 Segments Have Consistent Needs."}]} |
1,271 | mention the second point listed under the article 7(document storage period)? | 3 | [
"To be stored for ten years",
"to be stored for ten years"
] | [
"table/list",
"layout"
] | jpjf0226 | train | 556 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOydbXbrLK+G75z1zkt0ZCIjEx6Zzg9JgB2nO+3TOHGra62d3cR8COwgJAS5KJIkSZLkPfm/VwuQJEmSJPdIJZUkSZK8LamkkiRJkrcllVSSJEnytqSSSpIkSd6WVFJJkiTJ25JKKkmSJHlbUkklSZIkb0sqqSRJkuRtSSWVJEmSvC2ppJIkSZK3JZVUkiRJ8rakkkqSJEnellRSSZIkyduSSipJkiR5W1JJJUmSJG9LKqkkSZLkbUkllSRJkrwtqaSSJEm... | {"gt_parses": [{"question" : "mention the second point listed under the article 7(document storage period)?", "answer" : "To be stored for ten years"}, {"question" : "mention the second point listed under the article 7(document storage period)?", "answer" : "to be stored for ten years"}]} |
1,272 | what is article 4? | 2 | [
"(PRINCIPLES OF CREATING DOCUMENTS)",
"principles of creating documents",
"PRINCIPLES OF CREATING DOCUMENTS"
] | [
"form",
"layout"
] | jpjf0226 | train | 557 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOydbXbrPKuG75z1zgs6MvDIwCPj/ECSZTdp0+42cZ5y7bXd2NYHkh0hIaRcAkVRFEVxTv7v2QIURVEUxS1KSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVp... | {"gt_parses": [{"question" : "what is article 4?", "answer" : "(PRINCIPLES OF CREATING DOCUMENTS)"}, {"question" : "what is article 4?", "answer" : "principles of creating documents"}, {"question" : "what is article 4?", "answer" : "PRINCIPLES OF CREATING DOCUMENTS"}]} |
1,273 | Semi exclusive rights in how many countries? | 2 | [
"20",
"20 countries"
] | [
"others",
"free_text"
] | trjf0226 | train | 580 | "iVBORw0KGgoAAAANSUhEUgAABqgAAAi/CAAAAACUqUxvAAEAAElEQVR4nOzdaZLjqhIF4MOLuy/SKyNZmZKV8X4wCMnyVO2BKp8vortsGSFkVynNIHAZRERE8/rfpwtARER0DQMVERFNjYGKiIimxkBFRERTY6AiIqKpMVAREdHUGKiIiGhqDFRERDQ1BioiIpoaAxUREU2NgYqIiKbGQEVERFNjoCIioqkxUBER0dQYqIiIaGoMVERENDUGKiIimhoDFRERTY2BioiIpsZARUREU2OgIiKiqTFQERHR1BioiIhoagxUREQ0NQYqIiK... | {"gt_parses": [{"question" : "Semi exclusive rights in how many countries?", "answer" : "20"}, {"question" : "Semi exclusive rights in how many countries?", "answer" : "20 countries"}]} |
1,274 | what is the title of chapter 2? | 2 | [
"DOCUMENT STORAGE FUNCTIONS",
"document storage functions"
] | [
"form",
"layout"
] | jpjf0226 | train | 557 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOydbXbrPKuG75z1zgs6MvDIwCPj/ECSZTdp0+42cZ5y7bXd2NYHkh0hIaRcAkVRFEVxTv7v2QIURVEUxS1KSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVp... | {"gt_parses": [{"question" : "what is the title of chapter 2?", "answer" : "DOCUMENT STORAGE FUNCTIONS"}, {"question" : "what is the title of chapter 2?", "answer" : "document storage functions"}]} |
1,276 | What percent is the Supply Price / Royalty Rate? | 2 | [
"30% SUPPLY PRICE",
"30% supply price"
] | [
"form"
] | trjf0226 | train | 580 | "iVBORw0KGgoAAAANSUhEUgAABqgAAAi/CAAAAACUqUxvAAEAAElEQVR4nOzdaZLjqhIF4MOLuy/SKyNZmZKV8X4wCMnyVO2BKp8vortsGSFkVynNIHAZRERE8/rfpwtARER0DQMVERFNjYGKiIimxkBFRERTY6AiIqKpMVAREdHUGKiIiGhqDFRERDQ1BioiIpoaAxUREU2NgYqIiKbGQEVERFNjoCIioqkxUBER0dQYqIiIaGoMVERENDUGKiIimhoDFRERTY2BioiIpsZARUREU2OgIiKiqTFQERHR1BioiIhoagxUREQ0NQYqIiK... | {"gt_parses": [{"question" : "What percent is the Supply Price / Royalty Rate?", "answer" : "30% SUPPLY PRICE"}, {"question" : "What percent is the Supply Price / Royalty Rate?", "answer" : "30% supply price"}]} |
1,277 | What does article 5 in this document describes? | 2 | [
"(principles concerning document storage functions)",
"principles concerning document storage functions"
] | [
"form",
"layout"
] | jpjf0226 | train | 557 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOydbXbrPKuG75z1zgs6MvDIwCPj/ECSZTdp0+42cZ5y7bXd2NYHkh0hIaRcAkVRFEVxTv7v2QIURVEUxS1KSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVp... | {"gt_parses": [{"question" : "What does article 5 in this document describes?", "answer" : "(principles concerning document storage functions)"}, {"question" : "What does article 5 in this document describes?", "answer" : "principles concerning document storage functions"}]} |
1,278 | what is article 6? | 2 | [
"(DUTIES OF RESPONSIBLE PERSON IN CHARGE OF STORAGE AND PERSON IN CHARGE OF STORAGE)",
"duties of responsible person in charge of storage and person in charge of storage",
"DUTIES OF RESPONSIBLE PERSON IN CHARGE OF STORAGE AND PERSON IN CHARGE OF STORAGE"
] | [
"form",
"layout"
] | jpjf0226 | train | 557 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOydbXbrPKuG75z1zgs6MvDIwCPj/ECSZTdp0+42cZ5y7bXd2NYHkh0hIaRcAkVRFEVxTv7v2QIURVEUxS1KSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVpKSRVFURSnpZRUURRFcVp... | {"gt_parses": [{"question" : "what is article 6?", "answer" : "(DUTIES OF RESPONSIBLE PERSON IN CHARGE OF STORAGE AND PERSON IN CHARGE OF STORAGE)"}, {"question" : "what is article 6?", "answer" : "duties of responsible person in charge of storage and person in charge of storage"}, {"question" : "what is article 6?", "... |
1,279 | In how many countires, license to Exclusive rights are provided? | 2 | [
"60",
"60 COUNTRIES",
"in approximately 60 countries"
] | [
"form",
"free_text"
] | trjf0226 | train | 580 | "iVBORw0KGgoAAAANSUhEUgAABqgAAAi/CAAAAACUqUxvAAEAAElEQVR4nOzdaZLjqhIF4MOLuy/SKyNZmZKV8X4wCMnyVO2BKp8vortsGSFkVynNIHAZRERE8/rfpwtARER0DQMVERFNjYGKiIimxkBFRERTY6AiIqKpMVAREdHUGKiIiGhqDFRERDQ1BioiIpoaAxUREU2NgYqIiKbGQEVERFNjoCIioqkxUBER0dQYqIiIaGoMVERENDUGKiIimhoDFRERTY2BioiIpsZARUREU2OgIiKiqTFQERHR1BioiIhoagxUREQ0NQYqIiK... | {"gt_parses": [{"question" : "In how many countires, license to Exclusive rights are provided?", "answer" : "60"}, {"question" : "In how many countires, license to Exclusive rights are provided?", "answer" : "60 COUNTRIES"}, {"question" : "In how many countires, license to Exclusive rights are provided?", "answer" : "i... |
1,280 | what is the name of pediatric program? | 1 | [
"ACTOS",
"ACTOS PEDIATRIC PROGRAM"
] | [
"layout"
] | jfkf0226 | train | 560 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAakCAAAAACXAmxUAACWxklEQVR4nO39WbMr53knej5rc3OURFLUREnUPFjyoMFl2S5PyGW7bNdwyuU6PqfPRUd0REf3TX+JzPUx+qajO7qj45yeTpVdZbvkciFRnuShZFvWRI0URVIURZEUZ26SG32BGcgEMrGAxIuF3+/i5d7IfIdMgHs9K/FH4mwYAABpuHboBQAATChMAIBkKEwAgGQoTACAZChMAIBkKEwAgGQoTACAZChMAIBkKEwAgGQoTACAZChMAIBkKEwAgGQoTACAZChMAIBkKEw... | {"gt_parses": [{"question" : "what is the name of pediatric program?", "answer" : "ACTOS"}, {"question" : "what is the name of pediatric program?", "answer" : "ACTOS PEDIATRIC PROGRAM"}]} |
1,282 | What is the date mentioned in this page? | 1 | [
"5 October 2006"
] | [
"layout"
] | jfkf0226 | train | 560 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAakCAAAAACXAmxUAACWxklEQVR4nO39WbMr53knej5rc3OURFLUREnUPFjyoMFl2S5PyGW7bNdwyuU6PqfPRUd0REf3TX+JzPUx+qajO7qj45yeTpVdZbvkciFRnuShZFvWRI0URVIURZEUZ26SG32BGcgEMrGAxIuF3+/i5d7IfIdMgHs9K/FH4mwYAABpuHboBQAATChMAIBkKEwAgGQoTACAZChMAIBkKEwAgGQoTACAZChMAIBkKEwAgGQoTACAZChMAIBkKEwAgGQoTACAZChMAIBkKEw... | {"gt_parses": [{"question" : "What is the date mentioned in this page?", "answer" : "5 October 2006"}]} |
1,283 | What is the title of this document? | 8 | [
"CRITICAL SUCCESS FACTORS",
"Critical Success Factors"
] | [
"layout"
] | xqjf0226 | train | 573 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOyda5brqA6Fd+7qeUFGJjwyySPj/gDbgPEjj6o4p/a3un1SBoTALxlkcYsghBBCCLkG//u0AoQQQgghEzRMCCGEEHIZaJgQQggh5DLQMCGEEELIZaBhQgghhJDLQMOEEEIIIZeBhgkhhBBCLgMNE0IIIYRcBhomhBBCCLkMNEwIIYQQchlomBBCCCHkMtAwIYQQQshloGFCCCGEkMtAw4QQQgghl4GGCSGEEEIuAw0TQgghhFwGGiaEEEIIuQw0TAghhBB... | {"gt_parses": [{"question" : "What is the title of this document?", "answer" : "CRITICAL SUCCESS FACTORS"}, {"question" : "What is the title of this document?", "answer" : "Critical Success Factors"}]} |
1,287 | What is the title of this document? | 6 | [
"Consequences of IR"
] | [
"layout"
] | ynjf0226 | train | 570 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOydabqruA5FN++reVkZmeSRIY+M98M0BkwS0vrc7HWrcgi4EQSwLMtyN4AQQgghpA3+920BCCGEEEImqJgQQgghpBmomBBCCCGkGaiYEEIIIaQZqJgQQgghpBmomBBCCCGkGaiYEEIIIaQZqJgQQgghpBmomBBCCCGkGaiYEEIIIaQZqJgQQgghpBmomBBCCCGkGaiYEEIIIaQZqJgQQgghpBmomBBCCCGkGaiYEEIIIaQZqJgQQgghpBmomBBCCCGkGai... | {"gt_parses": [{"question" : "What is the title of this document?", "answer" : "Consequences of IR"}]} |
1,294 | What is the title of this page? | 17 | [
"ACTOS PLAN OVERVIEW",
"Actos plan overview"
] | [
"layout"
] | ynjf0226 | train | 565 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbKCAAAAABKPmlAAAEAAElEQVR4nOydZ5rsOgqGP89z9wW1MtDKjFbm+aHsULm7fLp4Z+5pl62Ak4QRQtMCx3Ecx3Gck/C/TwvgOI7jOI5Tcc3EcRzHcZzz4JqJ4ziO4zjnwTUTx3Ecx3HOg2smjuM4juOcB9dMHMdxHMc5D66ZOI7jOI5zHlwzcRzHcRznPLhm4jiO4zjOeXDNxHEcx3Gc8+CaieM4juM458E1E8dxHMdxzoNrJo7jOI7jnAfXTBzHcRzHOQ+umTiO4ziOcx5cM3Ecx3Ec5zy... | {"gt_parses": [{"question" : "What is the title of this page?", "answer" : "ACTOS PLAN OVERVIEW"}, {"question" : "What is the title of this page?", "answer" : "Actos plan overview"}]} |
1,295 | which are prescibed eariler in the treatment of type 2 diabetes under the title of "critical success factors"? | 17 | [
"TZD'S",
"TZD's"
] | [
"table/list",
"free_text"
] | ynjf0226 | train | 565 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbKCAAAAABKPmlAAAEAAElEQVR4nOydZ5rsOgqGP89z9wW1MtDKjFbm+aHsULm7fLp4Z+5pl62Ak4QRQtMCx3Ecx3Gck/C/TwvgOI7jOI5Tcc3EcRzHcZzz4JqJ4ziO4zjnwTUTx3Ecx3HOg2smjuM4juOcB9dMHMdxHMc5D66ZOI7jOI5zHlwzcRzHcRznPLhm4jiO4zjOeXDNxHEcx3Gc8+CaieM4juM458E1E8dxHMdxzoNrJo7jOI7jnAfXTBzHcRzHOQ+umTiO4ziOcx5cM3Ecx3Ec5zy... | {"gt_parses": [{"question" : "which are prescibed eariler in the treatment of type 2 diabetes under the title of "critical success factors"?", "answer" : "TZD'S"}, {"question" : "which are prescibed eariler in the treatment of type 2 diabetes under the title of "critical success factors"?", "answer" : "TZD's"}]} |
1,296 | What does the graph describes in this document? | 3 | [
"TZD SHARE OF ORAL MARKET",
"TZD Share of Oral Market"
] | [
"layout"
] | ynjf0226 | train | 586 | "iVBORw0KGgoAAAANSUhEUgAACJoAAAbLCAAAAABqVQHmAAEAAElEQVR4nOyda5qruA5FN/freUk1MskjQx4Z94dtMATyqFc4xV6nu5KAsQ0htpD1GCYQQgghhJyF/727A4QQQgghCxRNCCGEEHIiKJoQQggh5ERQNCGEEELIiaBoQgghhJATQdGEEEIIISeCogkhhBBCTgRFE0IIIYScCIomhBBCCDkRFE0IIYQQciIomhBCCCHkRFA0IYQQQsiJoGhCCCGEkBNB0YQQQgghJ4KiCSGEEEJOBEUTQgghhJwIiiaEEEIIOREUTQghhBB... | {"gt_parses": [{"question" : "What does the graph describes in this document?", "answer" : "TZD SHARE OF ORAL MARKET"}, {"question" : "What does the graph describes in this document?", "answer" : "TZD Share of Oral Market"}]} |
1,301 | What is the Plan TZD Share for the year 2003? | 3 | [
"19.7%"
] | [
"table/list"
] | ynjf0226 | train | 586 | "iVBORw0KGgoAAAANSUhEUgAACJoAAAbLCAAAAABqVQHmAAEAAElEQVR4nOyda5qruA5FN/freUk1MskjQx4Z94dtMATyqFc4xV6nu5KAsQ0htpD1GCYQQgghhJyF/727A4QQQgghCxRNCCGEEHIiKJoQQggh5ERQNCGEEELIiaBoQgghhJATQdGEEEIIISeCogkhhBBCTgRFE0IIIYScCIomhBBCCDkRFE0IIYQQciIomhBCCCHkRFA0IYQQQsiJoGhCCCGEkBNB0YQQQgghJ4KiCSGEEEJOBEUTQgghhJwIiiaEEEIIOREUTQghhBB... | {"gt_parses": [{"question" : "What is the Plan TZD Share for the year 2003?", "answer" : "19.7%"}]} |
1,303 | Which year has 13.3% Oral share (TZD)? | 3 | [
"2000"
] | [
"table/list"
] | ynjf0226 | train | 586 | "iVBORw0KGgoAAAANSUhEUgAACJoAAAbLCAAAAABqVQHmAAEAAElEQVR4nOyda5qruA5FN/freUk1MskjQx4Z94dtMATyqFc4xV6nu5KAsQ0htpD1GCYQQgghhJyF/727A4QQQgghCxRNCCGEEHIiKJoQQggh5ERQNCGEEELIiaBoQgghhJATQdGEEEIIISeCogkhhBBCTgRFE0IIIYScCIomhBBCCDkRFE0IIYQQciIomhBCCCHkRFA0IYQQQsiJoGhCCCGEkBNB0YQQQgghJ4KiCSGEEEJOBEUTQgghhJwIiiaEEEIIOREUTQghhBB... | {"gt_parses": [{"question" : "Which year has 13.3% Oral share (TZD)?", "answer" : "2000"}]} |
1,304 | which has a superior lipid profile(v. avandia and others) under the title of "strength/opportunities? | 17 | [
"ACTOS"
] | [
"table/list",
"free_text"
] | ynjf0226 | train | 565 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbKCAAAAABKPmlAAAEAAElEQVR4nOydZ5rsOgqGP89z9wW1MtDKjFbm+aHsULm7fLp4Z+5pl62Ak4QRQtMCx3Ecx3Gck/C/TwvgOI7jOI5Tcc3EcRzHcZzz4JqJ4ziO4zjnwTUTx3Ecx3HOg2smjuM4juOcB9dMHMdxHMc5D66ZOI7jOI5zHlwzcRzHcRznPLhm4jiO4zjOeXDNxHEcx3Gc8+CaieM4juM458E1E8dxHMdxzoNrJo7jOI7jnAfXTBzHcRzHOQ+umTiO4ziOcx5cM3Ecx3Ec5zy... | {"gt_parses": [{"question" : "which has a superior lipid profile(v. avandia and others) under the title of "strength/opportunities?", "answer" : "ACTOS"}]} |
1,309 | Which study's synopsis is this? | 4 | [
"Clinical Study",
"clinical"
] | [
"layout"
] | jfkf0226 | train | 571 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAakCAAAAACXAmxUAAEAAElEQVR4nOyda7akKgxGU3f1vOCMDBwZODLvD1F5BAQflFX17bXa6iMhCQ8VMeJrIgAAAACAZ/Dfux0AAAAAAFjAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAA... | {"gt_parses": [{"question" : "Which study's synopsis is this?", "answer" : "Clinical Study"}, {"question" : "Which study's synopsis is this?", "answer" : "clinical"}]} |
1,310 | what is the code mentioned under the title of clinical study synopsis? | 4 | [
"01-06-TL-OPI-527"
] | [
"layout"
] | jfkf0226 | train | 571 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAakCAAAAACXAmxUAAEAAElEQVR4nOyda7akKgxGU3f1vOCMDBwZODLvD1F5BAQflFX17bXa6iMhCQ8VMeJrIgAAAACAZ/Dfux0AAAAAAFjAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAA... | {"gt_parses": [{"question" : "what is the code mentioned under the title of clinical study synopsis?", "answer" : "01-06-TL-OPI-527"}]} |
1,311 | When was expert advisory meeting ? | 4 | [
"4 OCTOBER 2006",
"4 october 2006"
] | [
"table/list",
"free_text"
] | jfkf0226 | train | 571 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAakCAAAAACXAmxUAAEAAElEQVR4nOyda7akKgxGU3f1vOCMDBwZODLvD1F5BAQflFX17bXa6iMhCQ8VMeJrIgAAAACAZ/Dfux0AAAAAAFjAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAAAjwEDEwAAAAA8BgxMAAAAAPAYMDABAAAAwGPAwAQAAAA... | {"gt_parses": [{"question" : "When was expert advisory meeting ?", "answer" : "4 OCTOBER 2006"}, {"question" : "When was expert advisory meeting ?", "answer" : "4 october 2006"}]} |
1,312 | What is the title of this document? | 3 | [
"OVERVIEW OF NOVEMBER 2006 SUBMISSION",
"Overview of November 2006 Submission"
] | [
"layout"
] | jfkf0226 | train | 599 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAakCAAAAACXAmxUAADMN0lEQVR4nOzdW5qiOhSG4eV+el5JjSxxZIkjY19whpUQFDDq915YXZAj2FUp/MVbIwAAAHX4790DAAAA6LEwAQAA1WBhAgAAqsHCBAAAVIOFCQAAqAYLEwAAUA0WJgAAoBosTAAAQDVYmAAAgGqwMAEAANVgYQIAAKrBwgQAAFSDhQkAAKgGCxMAAFANFiYAAKAaLEwAAEA1WJgAAIBqsDABAADVYGECAACqwcIEAABUg4UJAACoBgsTAABQDRYmAACgGixMAABANVi... | {"gt_parses": [{"question" : "What is the title of this document?", "answer" : "OVERVIEW OF NOVEMBER 2006 SUBMISSION"}, {"question" : "What is the title of this document?", "answer" : "Overview of November 2006 Submission"}]} |
1,313 | What is the full form of PPSR? | 3 | [
"PROPOSED PEDIATRIC STUDY REQUEST",
"Proposed Pediatric Study Request"
] | [
"table/list",
"others"
] | jfkf0226 | train | 599 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAakCAAAAACXAmxUAADMN0lEQVR4nOzdW5qiOhSG4eV+el5JjSxxZIkjY19whpUQFDDq915YXZAj2FUp/MVbIwAAAHX4790DAAAA6LEwAQAA1WBhAgAAqsHCBAAAVIOFCQAAqAYLEwAAUA0WJgAAoBosTAAAQDVYmAAAgGqwMAEAANVgYQIAAKrBwgQAAFSDhQkAAKgGCxMAAFANFiYAAKAaLEwAAEA1WJgAAIBqsDABAADVYGECAACqwcIEAABUg4UJAACoBgsTAABQDRYmAACgGixMAABANVi... | {"gt_parses": [{"question" : "What is the full form of PPSR?", "answer" : "PROPOSED PEDIATRIC STUDY REQUEST"}, {"question" : "What is the full form of PPSR?", "answer" : "Proposed Pediatric Study Request"}]} |
1,316 | What study is described in the table given? | 7 | [
"PLACEBO- CONTROLLED DOSE RANGING STUDY",
"Glycemic Parameters in a 26-Week Placebo-Controlled Dose-Ranging Study."
] | [
"table/list",
"layout"
] | hfkf0226 | train | 605 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAiZCAAAAACwoiH0AAEAAElEQVR4nOyda5ajOq+GX8765iVlZDIjkxiZzg/5BiG1q7tzq5Se1U0BvglDELJle3EkSZIkyZvyf68WIEmSJElukloqSZIkeV9SSyVJkiTvS2qpJEmS5H1JLZUkSZK8L6mlkiRJkvcltVSSJEnyvqSWSpIkSd6X1FJJkiTJ+5JaKkmSJHlfUkslSZIk70tqqSRJkuR9SS2VJEmSvC+ppZIkSZL3JbVUkiRJ8r6klkqSJEnel9RSSZIkyfuSWipJkiR5X1JLJUmSJO9... | {"gt_parses": [{"question" : "What study is described in the table given?", "answer" : "PLACEBO- CONTROLLED DOSE RANGING STUDY"}, {"question" : "What study is described in the table given?", "answer" : "Glycemic Parameters in a 26-Week Placebo-Controlled Dose-Ranging Study."}]} |
1,317 | Which parameters are considered for the study(see heading of table 2)? | 7 | [
"GLYCEMIC",
"Glycemic Parameters"
] | [
"layout"
] | hfkf0226 | train | 605 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAiZCAAAAACwoiH0AAEAAElEQVR4nOyda5ajOq+GX8765iVlZDIjkxiZzg/5BiG1q7tzq5Se1U0BvglDELJle3EkSZIkyZvyf68WIEmSJElukloqSZIkeV9SSyVJkiTvS2qpJEmS5H1JLZUkSZK8L6mlkiRJkvcltVSSJEnyvqSWSpIkSd6X1FJJkiTJ+5JaKkmSJHlfUkslSZIk70tqqSRJkuR9SS2VJEmSvC+ppZIkSZL3JbVUkiRJ8r6klkqSJEnel9RSSZIkyfuSWipJkiR5X1JLJUmSJO9... | {"gt_parses": [{"question" : "Which parameters are considered for the study(see heading of table 2)?", "answer" : "GLYCEMIC"}, {"question" : "Which parameters are considered for the study(see heading of table 2)?", "answer" : "Glycemic Parameters"}]} |
1,318 | Prior to what, the patients entered an 8 week washout/run-in-period? | 7 | [
"double-blind treatment"
] | [
"free_text"
] | hfkf0226 | train | 605 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAiZCAAAAACwoiH0AAEAAElEQVR4nOyda5ajOq+GX8765iVlZDIjkxiZzg/5BiG1q7tzq5Se1U0BvglDELJle3EkSZIkyZvyf68WIEmSJElukloqSZIkeV9SSyVJkiTvS2qpJEmS5H1JLZUkSZK8L6mlkiRJkvcltVSSJEnyvqSWSpIkSd6X1FJJkiTJ+5JaKkmSJHlfUkslSZIk70tqqSRJkuR9SS2VJEmSvC+ppZIkSZL3JbVUkiRJ8r6klkqSJEnel9RSSZIkyfuSWipJkiR5X1JLJUmSJO9... | {"gt_parses": [{"question" : "Prior to what, the patients entered an 8 week washout/run-in-period?", "answer" : "double-blind treatment"}]} |
1,320 | What is the floor supply price? | 5 | [
"$0.17 / 30 mg or Takeda's cost from site of lowest cost"
] | [
"free_text"
] | trjf0226 | train | 579 | "iVBORw0KGgoAAAANSUhEUgAABqYAAAi9CAAAAADHqN3XAAEAAElEQVR4nOyda5rrKK+FV87zzUvKyCRGhhgZ5wdgYyepW1cl1K71du9yjLkInFgWCLhUEEIIIavyf68WgBBCCHkM1RQhhJCFoZoihBCyMFRThBBCFoZqihBCyMJQTRFCCFkYqilCCCELQzVFCCFkYaimCCGELAzVFCGEkIWhmiKEELIwVFOEEEIWhmqKEELIwlBNEUIIWRiqKUIIIQtDNUUIIWRhqKYIIYQsDNUUIYSQhaGaIoQQsjBUU4QQQhaGaooQQsjCUE0RQgh... | {"gt_parses": [{"question" : "What is the floor supply price?", "answer" : "$0.17 / 30 mg or Takeda's cost from site of lowest cost"}]} |
1,321 | What is the royalty adjustment if generic enters the market ? | 5 | [
"50%",
"50% royalty adjustment"
] | [
"free_text"
] | trjf0226 | train | 579 | "iVBORw0KGgoAAAANSUhEUgAABqYAAAi9CAAAAADHqN3XAAEAAElEQVR4nOyda5rrKK+FV87zzUvKyCRGhhgZ5wdgYyepW1cl1K71du9yjLkInFgWCLhUEEIIIavyf68WgBBCCHkM1RQhhJCFoZoihBCyMFRThBBCFoZqihBCyMJQTRFCCFkYqilCCCELQzVFCCFkYaimCCGELAzVFCGEkIWhmiKEELIwVFOEEEIWhmqKEELIwlBNEUIIWRiqKUIIIQtDNUUIIWRhqKYIIYQsDNUUIYSQhaGaIoQQsjBUU4QQQhaGaooQQsjCUE0RQgh... | {"gt_parses": [{"question" : "What is the royalty adjustment if generic enters the market ?", "answer" : "50%"}, {"question" : "What is the royalty adjustment if generic enters the market ?", "answer" : "50% royalty adjustment"}]} |
1,322 | what is the promotional trails data usage for( Lilly in exclusive) ? | 5 | [
"Split of 70/30 (Lilly in Exclusive)",
"split of 70/30 (Lilly in exclusive)",
"Split of 70/30"
] | [
"free_text"
] | trjf0226 | train | 579 | "iVBORw0KGgoAAAANSUhEUgAABqYAAAi9CAAAAADHqN3XAAEAAElEQVR4nOyda5rrKK+FV87zzUvKyCRGhhgZ5wdgYyepW1cl1K71du9yjLkInFgWCLhUEEIIIavyf68WgBBCCHkM1RQhhJCFoZoihBCyMFRThBBCFoZqihBCyMJQTRFCCFkYqilCCCELQzVFCCFkYaimCCGELAzVFCGEkIWhmiKEELIwVFOEEEIWhmqKEELIwlBNEUIIWRiqKUIIIQtDNUUIIWRhqKYIIYQsDNUUIYSQhaGaIoQQsjBUU4QQQhaGaooQQsjCUE0RQgh... | {"gt_parses": [{"question" : "what is the promotional trails data usage for( Lilly in exclusive) ?", "answer" : "Split of 70/30 (Lilly in Exclusive)"}, {"question" : "what is the promotional trails data usage for( Lilly in exclusive) ?", "answer" : "split of 70/30 (Lilly in exclusive)"}, {"question" : "what is the prom... |
1,323 | What is the title mentioned in this document? | 9 | [
"CSF'S AND MARKETING OBJECTIVES",
"CSF's and Marketing Objectives"
] | [
"layout"
] | xqjf0226 | train | 582 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOyd65asLK+FZ+3x3RfUlQWvLPHKsn9wRjxUd3WXvd48YyxXKxACWoo4jQ+FYRiGYRjGPfi/TztgGIZhGIaRsYGJYRiGYRi3wQYmhmEYhmHcBhuYGIZhGIZxG2xgYhiGYRjGbbCBiWEYhmEYt8EGJoZhGIZh3AYbmBiGYRiGcRtsYGIYhmEYxm2wgYlhGIZhGLfBBiaGYRiGYdwGG5gYhmEYhnEbbGBiGIZhGMZtsIGJYRiGYRi3wQYmhmEYhmHcBhuYGIZ... | {"gt_parses": [{"question" : "What is the title mentioned in this document?", "answer" : "CSF'S AND MARKETING OBJECTIVES"}, {"question" : "What is the title mentioned in this document?", "answer" : "CSF's and Marketing Objectives"}]} |
1,324 | What is the promotional trials data usage for (semi exclusive)? | 5 | [
"50/50 in Semi-exclusive"
] | [
"free_text"
] | trjf0226 | train | 579 | "iVBORw0KGgoAAAANSUhEUgAABqYAAAi9CAAAAADHqN3XAAEAAElEQVR4nOyda5rrKK+FV87zzUvKyCRGhhgZ5wdgYyepW1cl1K71du9yjLkInFgWCLhUEEIIIavyf68WgBBCCHkM1RQhhJCFoZoihBCyMFRThBBCFoZqihBCyMJQTRFCCFkYqilCCCELQzVFCCFkYaimCCGELAzVFCGEkIWhmiKEELIwVFOEEEIWhmqKEELIwlBNEUIIWRiqKUIIIQtDNUUIIWRhqKYIIYQsDNUUIYSQhaGaIoQQsjBUU4QQQhaGaooQQsjCUE0RQgh... | {"gt_parses": [{"question" : "What is the promotional trials data usage for (semi exclusive)?", "answer" : "50/50 in Semi-exclusive"}]} |
1,325 | what is the name of the plan review ? | 1 | [
"MARKETING PLAN REVIEW",
"Marketing plan review.",
"MARKETING PLAN"
] | [
"layout"
] | ynjf0226 | train | 583 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbKCAAAAABKPmlAAAEAAElEQVR4nOzdYXriyq624cffdeZVYmSSRoY0Mn8/yhBIQjrdqxs7m/c+Z/dKwNiFA1ioVFXLioiIiMhB/L+9GyAiIiJypchEREREjkORiYiIiByHIhMRERE5DkUmIiIichyKTEREROQ4FJmIiIjIcSgyERERkeNQZCIiIiLHochEREREjkORiYiIiByHIhMRERE5DkUmIiIichyKTEREROQ4FJmIiIjIcSgyERERkeNQZCIiIiLHochEREREjkORiYiIiByHIhMRERE... | {"gt_parses": [{"question" : "what is the name of the plan review ?", "answer" : "MARKETING PLAN REVIEW"}, {"question" : "what is the name of the plan review ?", "answer" : "Marketing plan review."}, {"question" : "what is the name of the plan review ?", "answer" : "MARKETING PLAN"}]} |
1,326 | What is the heading of this document? | 1 | [
"ACTOS FDA RESPONSE STRATEGY",
"ACTOS FDA Response Strategy"
] | [
"layout"
] | yljf0226 | train | 620 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOzdbZrbuo4t4KX79LwAjwzQyAiODPcHSH3YcqWyk5woVevt3hVLoijalWOEFEQuCSIionv6f3+7AURERO8wSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBE... | {"gt_parses": [{"question" : "What is the heading of this document?", "answer" : "ACTOS FDA RESPONSE STRATEGY"}, {"question" : "What is the heading of this document?", "answer" : "ACTOS FDA Response Strategy"}]} |
1,327 | What is the last revision date mentioned in this document? | 1 | [
"August 7, 2002"
] | [
"form"
] | yljf0226 | train | 620 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOzdbZrbuo4t4KX79LwAjwzQyAiODPcHSH3YcqWyk5woVevt3hVLoijalWOEFEQuCSIionv6f3+7AURERO8wSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBE... | {"gt_parses": [{"question" : "What is the last revision date mentioned in this document?", "answer" : "August 7, 2002"}]} |
1,328 | What is the goal of TPNA? | 1 | [
"to supply justification to support maintaining current labeling."
] | [
"table/list"
] | yljf0226 | train | 620 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOzdbZrbuo4t4KX79LwAjwzQyAiODPcHSH3YcqWyk5woVevt3hVLoijalWOEFEQuCSIionv6f3+7AURERO8wSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBER0W0xSBE... | {"gt_parses": [{"question" : "What is the goal of TPNA?", "answer" : "to supply justification to support maintaining current labeling."}]} |
1,329 | what is the first point given in table for bladder cancer alongside of clinical findings ? | 4 | [
"OBSERVED DURING PRECLINICAL STUDIES IN RATS",
"observed during preclinical studies in rats"
] | [
"table/list"
] | trjf0226 | train | 575 | "iVBORw0KGgoAAAANSUhEUgAABqcAAAi+CAAAAACu/sRHAAEAAElEQVR4nOzdWZqrOhKF0U19d16ER6bQyByMjHqQAIHtTDsbWz75r6p70qYRckeglmEWAADd+t+rMwAAwAeIUwCAnhGnAAA9I04BAHpGnAIA9Iw4BQDoGXEKANAz4hQAoGfEKQBAz4hTAICeEacAAD0jTgEAekacAgD0jDgFAOgZcQoA0DPiFACgZ8QpAEDPiFMAgJ4RpwAAPSNOAQB6RpwCAPSMOAUA6BlxCgDQM+IUAKBnxCkAQM+IUwCAnhGnAAA9I04BAHpGnAI... | {"gt_parses": [{"question" : "what is the first point given in table for bladder cancer alongside of clinical findings ?", "answer" : "OBSERVED DURING PRECLINICAL STUDIES IN RATS"}, {"question" : "what is the first point given in table for bladder cancer alongside of clinical findings ?", "answer" : "observed during pr... |
1,331 | Mention the year given for Actos? | 1 | [
"2004",
"Actos 2004"
] | [
"layout"
] | ynjf0226 | train | 583 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbKCAAAAABKPmlAAAEAAElEQVR4nOzdYXriyq624cffdeZVYmSSRoY0Mn8/yhBIQjrdqxs7m/c+Z/dKwNiFA1ioVFXLioiIiMhB/L+9GyAiIiJypchEREREjkORiYiIiByHIhMRERE5DkUmIiIichyKTEREROQ4FJmIiIjIcSgyERERkeNQZCIiIiLHochEREREjkORiYiIiByHIhMRERE5DkUmIiIichyKTEREROQ4FJmIiIjIcSgyERERkeNQZCIiIiLHochEREREjkORiYiIiByHIhMRERE... | {"gt_parses": [{"question" : "Mention the year given for Actos?", "answer" : "2004"}, {"question" : "Mention the year given for Actos?", "answer" : "Actos 2004"}]} |
1,333 | what is the percentage of TZD share in the year 2000 ? | 4 | [
"40.3%"
] | [
"table/list"
] | ynjf0226 | train | 584 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOydabqruA5FN++reVl3ZJJHFnlkvB+mMV1CEhJ8wl5V9ySAG+HQyLIsNy0IIYQQQurgf2cLQAghhBDSQ8WEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UD... | {"gt_parses": [{"question" : "what is the percentage of TZD share in the year 2000 ?", "answer" : "40.3%"}]} |
1,335 | what is Actos TRx (000s) in the year 2003 ? | 4 | [
"9,497"
] | [
"table/list"
] | ynjf0226 | train | 584 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOydabqruA5FN++reVl3ZJJHFnlkvB+mMV1CEhJ8wl5V9ySAG+HQyLIsNy0IIYQQQurgf2cLQAghhBDSQ8WEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UD... | {"gt_parses": [{"question" : "what is Actos TRx (000s) in the year 2003 ?", "answer" : "9,497"}]} |
1,337 | how much percent of drug quantity present in rezulin under the title of 'clinical findings'? | 4 | [
"1.7%",
"1.7"
] | [
"table/list"
] | trjf0226 | train | 575 | "iVBORw0KGgoAAAANSUhEUgAABqcAAAi+CAAAAACu/sRHAAEAAElEQVR4nOzdWZqrOhKF0U19d16ER6bQyByMjHqQAIHtTDsbWz75r6p70qYRckeglmEWAADd+t+rMwAAwAeIUwCAnhGnAAA9I04BAHpGnAIA9Iw4BQDoGXEKANAz4hQAoGfEKQBAz4hTAICeEacAAD0jTgEAekacAgD0jDgFAOgZcQoA0DPiFACgZ8QpAEDPiFMAgJ4RpwAAPSNOAQB6RpwCAPSMOAUA6BlxCgDQM+IUAKBnxCkAQM+IUwCAnhGnAAA9I04BAHpGnAI... | {"gt_parses": [{"question" : "how much percent of drug quantity present in rezulin under the title of 'clinical findings'?", "answer" : "1.7%"}, {"question" : "how much percent of drug quantity present in rezulin under the title of 'clinical findings'?", "answer" : "1.7"}]} |
1,339 | what is the percentage of plan TZD share in the year 2004 ? | 4 | [
"42.9%"
] | [
"table/list"
] | ynjf0226 | train | 584 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOydabqruA5FN++reVl3ZJJHFnlkvB+mMV1CEhJ8wl5V9ySAG+HQyLIsNy0IIYQQQurgf2cLQAghhBDSQ8WEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UD... | {"gt_parses": [{"question" : "what is the percentage of plan TZD share in the year 2004 ?", "answer" : "42.9%"}]} |
1,340 | how much percent of placebo present in avandia alongside of the clinical findings? | 4 | [
"0.20%",
"0.20"
] | [
"table/list"
] | trjf0226 | train | 575 | "iVBORw0KGgoAAAANSUhEUgAABqcAAAi+CAAAAACu/sRHAAEAAElEQVR4nOzdWZqrOhKF0U19d16ER6bQyByMjHqQAIHtTDsbWz75r6p70qYRckeglmEWAADd+t+rMwAAwAeIUwCAnhGnAAA9I04BAHpGnAIA9Iw4BQDoGXEKANAz4hQAoGfEKQBAz4hTAICeEacAAD0jTgEAekacAgD0jDgFAOgZcQoA0DPiFACgZ8QpAEDPiFMAgJ4RpwAAPSNOAQB6RpwCAPSMOAUA6BlxCgDQM+IUAKBnxCkAQM+IUwCAnhGnAAA9I04BAHpGnAI... | {"gt_parses": [{"question" : "how much percent of placebo present in avandia alongside of the clinical findings?", "answer" : "0.20%"}, {"question" : "how much percent of placebo present in avandia alongside of the clinical findings?", "answer" : "0.20"}]} |
1,341 | in which month and the year the launch of Merck's PPAR's took place? | 4 | [
"FEB 2005",
"feb 2005"
] | [
"figure/diagram",
"others"
] | ynjf0226 | train | 584 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOydabqruA5FN++reVl3ZJJHFnlkvB+mMV1CEhJ8wl5V9ySAG+HQyLIsNy0IIYQQQurgf2cLQAghhBDSQ8WEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UD... | {"gt_parses": [{"question" : "in which month and the year the launch of Merck's PPAR's took place?", "answer" : "FEB 2005"}, {"question" : "in which month and the year the launch of Merck's PPAR's took place?", "answer" : "feb 2005"}]} |
1,342 | what is the TZD's TRx (000s) in the year 2005 ? | 4 | [
"22,902"
] | [
"table/list"
] | ynjf0226 | train | 584 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAbICAAAAADoNKN1AAEAAElEQVR4nOydabqruA5FN++reVl3ZJJHFnlkvB+mMV1CEhJ8wl5V9ySAG+HQyLIsNy0IIYQQQurgf2cLQAghhBDSQ8WEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UDFhBBCCCHVQMWEEEIIIdVAxYQQQggh1UD... | {"gt_parses": [{"question" : "what is the TZD's TRx (000s) in the year 2005 ?", "answer" : "22,902"}]} |
1,343 | what is the total number of all claims under the title of "summary of litigation risk in the ous territories"? | 4 | [
"10"
] | [
"table/list"
] | trjf0226 | train | 575 | "iVBORw0KGgoAAAANSUhEUgAABqcAAAi+CAAAAACu/sRHAAEAAElEQVR4nOzdWZqrOhKF0U19d16ER6bQyByMjHqQAIHtTDsbWz75r6p70qYRckeglmEWAADd+t+rMwAAwAeIUwCAnhGnAAA9I04BAHpGnAIA9Iw4BQDoGXEKANAz4hQAoGfEKQBAz4hTAICeEacAAD0jTgEAekacAgD0jDgFAOgZcQoA0DPiFACgZ8QpAEDPiFMAgJ4RpwAAPSNOAQB6RpwCAPSMOAUA6BlxCgDQM+IUAKBnxCkAQM+IUwCAnhGnAAA9I04BAHpGnAI... | {"gt_parses": [{"question" : "what is the total number of all claims under the title of "summary of litigation risk in the ous territories"?", "answer" : "10"}]} |
1,344 | what is the first TZD used for type 2 patients ? | 13 | [
"ACTOS",
"Actos"
] | [
"table/list",
"free_text"
] | ynjf0226 | train | 585 | "iVBORw0KGgoAAAANSUhEUgAACJoAAAbLCAAAAABqVQHmAAEAAElEQVR4nOyd65qsKg6GP+fZ90X6yhKuzHBlzg88AKJ16O4qe9X3zuzVpUIIqBDDaZhACCGEEHIV/vduBQghhBBCNmiaEEIIIeRC0DQhhBBCyIWgaUIIIYSQC0HThBBCCCEXgqYJIYQQQi4ETRNCCCGEXAiaJoQQQgi5EDRNCCGEEHIhaJoQQggh5ELQNCGEEELIhaBpQgghhJALQdOEEEIIIReCpgkhhBBCLgRNE0IIIYRcCJomhBBCCLkQNE0IIYQQciFomhBCCCH... | {"gt_parses": [{"question" : "what is the first TZD used for type 2 patients ?", "answer" : "ACTOS"}, {"question" : "what is the first TZD used for type 2 patients ?", "answer" : "Actos"}]} |
1,345 | For which type of diabetes the TZD's prescribed earlier in treatment? | 13 | [
"Type 2 diabetes"
] | [
"table/list",
"free_text"
] | ynjf0226 | train | 585 | "iVBORw0KGgoAAAANSUhEUgAACJoAAAbLCAAAAABqVQHmAAEAAElEQVR4nOyd65qsKg6GP+fZ90X6yhKuzHBlzg88AKJ16O4qe9X3zuzVpUIIqBDDaZhACCGEEHIV/vduBQghhBBCNmiaEEIIIeRC0DQhhBBCyIWgaUIIIYSQC0HThBBCCCEXgqYJIYQQQi4ETRNCCCGEXAiaJoQQQgi5EDRNCCGEEHIhaJoQQggh5ELQNCGEEELIhaBpQgghhJALQdOEEEIIIReCpgkhhBBCLgRNE0IIIYRcCJomhBBCCLkQNE0IIYQQciFomhBCCCH... | {"gt_parses": [{"question" : "For which type of diabetes the TZD's prescribed earlier in treatment?", "answer" : "Type 2 diabetes"}]} |
1,346 | what has to be establish as the the best OAD medication by treating insulin resistance ? | 13 | [
"ACTOS",
"Actos"
] | [
"free_text"
] | ynjf0226 | train | 585 | "iVBORw0KGgoAAAANSUhEUgAACJoAAAbLCAAAAABqVQHmAAEAAElEQVR4nOyd65qsKg6GP+fZ90X6yhKuzHBlzg88AKJ16O4qe9X3zuzVpUIIqBDDaZhACCGEEHIV/vduBQghhBBCNmiaEEIIIeRC0DQhhBBCyIWgaUIIIYSQC0HThBBCCCEXgqYJIYQQQi4ETRNCCCGEXAiaJoQQQgi5EDRNCCGEEHIhaJoQQggh5ELQNCGEEELIhaBpQgghhJALQdOEEEIIIReCpgkhhBBCLgRNE0IIIYRcCJomhBBCCLkQNE0IIYQQciFomhBCCCH... | {"gt_parses": [{"question" : "what has to be establish as the the best OAD medication by treating insulin resistance ?", "answer" : "ACTOS"}, {"question" : "what has to be establish as the the best OAD medication by treating insulin resistance ?", "answer" : "Actos"}]} |
1,347 | What is the Specific example given? | 2 | [
"pioglitazone: need to commit to studies to investigate certain signals",
"Pioglitazone: Need to commit to studies to investigate certain signals"
] | [
"form"
] | gmjf0226 | train | 544 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOyda3rkKLOEo87z7UvplRFaWYVWpvMjASHVxWW33ZZ74p1pV0ncElCRQAK6rDDGGGPOyf/9tADGGGPMI6ykjDHGnBYrKWOMMafFSsoYY8xpsZIyxhhzWqykjDHGnBYrKWOMMafFSsoYY8xpsZIyxhhzWqykjDHGnBYrKWOMMafFSuoFBOmnZfgPI9fAT+Py/3kk6Kdl+BkuPmDWGGPMWfFIyhhjzGmxkjLGGHNarKSMMcacFispY4wxp8VKyhhjzGmxkjL... | {"gt_parses": [{"question" : "What is the Specific example given?", "answer" : "pioglitazone: need to commit to studies to investigate certain signals"}, {"question" : "What is the Specific example given?", "answer" : "Pioglitazone: Need to commit to studies to investigate certain signals"}]} |
1,348 | what is the month and year of overview of submission ? | 2 | [
"NOVEMBER 2006",
"November 2006"
] | [
"layout"
] | jfkf0226 | train | 588 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAakCAAAAACXAmxUAAEAAElEQVR4nOzd67qqKhSAYdrPui+ZVwZdmXRl7h+eQAaI5oHqe3/UWsphoM4kG9mjUwAAAHX47+4AAAAARkxMAABANZiYAACAajAxAQAA1WBiAgAAqsHEBAAAVIOJCQAAqAYTEwAAUA0mJgAAoBpMTAAAQDWYmAAAgGowMQEAANVgYgIAAKrBxAQAAFSDiQkAAKgGExMAAFANJiYAAKAaTEwAAEA1mJgAAIBqMDEBAADVYGICAACqwcQEAABUg4kJAACoBhMTAABQDSY... | {"gt_parses": [{"question" : "what is the month and year of overview of submission ?", "answer" : "NOVEMBER 2006"}, {"question" : "what is the month and year of overview of submission ?", "answer" : "November 2006"}]} |
1,349 | Which country would have similar interest as in Europe? | 2 | [
"usa",
"USA"
] | [
"free_text"
] | gmjf0226 | train | 544 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOyda3rkKLOEo87z7UvplRFaWYVWpvMjASHVxWW33ZZ74p1pV0ncElCRQAK6rDDGGGPOyf/9tADGGGPMI6ykjDHGnBYrKWOMMafFSsoYY8xpsZIyxhhzWqykjDHGnBYrKWOMMafFSsoYY8xpsZIyxhhzWqykjDHGnBYrKWOMMafFSuoFBOmnZfgPI9fAT+Py/3kk6Kdl+BkuPmDWGGPMWfFIyhhjzGmxkjLGGHNarKSMMcacFispY4wxp8VKyhhjzGmxkjL... | {"gt_parses": [{"question" : "Which country would have similar interest as in Europe?", "answer" : "usa"}, {"question" : "Which country would have similar interest as in Europe?", "answer" : "USA"}]} |
1,350 | what is included in the summary document ? | 2 | [
"includes benefit-risk assessment",
"benefit risk assessment",
"(includes benefit-risk assessment)"
] | [
"others",
"table/list",
"free_text"
] | jfkf0226 | train | 588 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAakCAAAAACXAmxUAAEAAElEQVR4nOzd67qqKhSAYdrPui+ZVwZdmXRl7h+eQAaI5oHqe3/UWsphoM4kG9mjUwAAAHX47+4AAAAARkxMAABANZiYAACAajAxAQAA1WBiAgAAqsHEBAAAVIOJCQAAqAYTEwAAUA0mJgAAoBpMTAAAQDWYmAAAgGowMQEAANVgYgIAAKrBxAQAAFSDiQkAAKgGExMAAFANJiYAAKAaTEwAAEA1mJgAAIBqMDEBAADVYGICAACqwcQEAABUg4kJAACoBhMTAABQDSY... | {"gt_parses": [{"question" : "what is included in the summary document ?", "answer" : "includes benefit-risk assessment"}, {"question" : "what is included in the summary document ?", "answer" : "benefit risk assessment"}, {"question" : "what is included in the summary document ?", "answer" : "(includes benefit-risk ass... |
1,351 | What is the Suggestion from Glyn? | 2 | [
"tgrd would formulate direct risk management plan and obtain japan's input",
"TGRD would formulate direct Risk Management plan and obtain Japan's input"
] | [
"form"
] | gmjf0226 | train | 544 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOyda3rkKLOEo87z7UvplRFaWYVWpvMjASHVxWW33ZZ74p1pV0ncElCRQAK6rDDGGGPOyf/9tADGGGPMI6ykjDHGnBYrKWOMMafFSsoYY8xpsZIyxhhzWqykjDHGnBYrKWOMMafFSsoYY8xpsZIyxhhzWqykjDHGnBYrKWOMMafFSuoFBOmnZfgPI9fAT+Py/3kk6Kdl+BkuPmDWGGPMWfFIyhhjzGmxkjLGGHNarKSMMcacFispY4wxp8VKyhhjzGmxkjL... | {"gt_parses": [{"question" : "What is the Suggestion from Glyn?", "answer" : "tgrd would formulate direct risk management plan and obtain japan's input"}, {"question" : "What is the Suggestion from Glyn?", "answer" : "TGRD would formulate direct Risk Management plan and obtain Japan's input"}]} |
1,352 | what is the executive summary of bladder cancer cases ? | 2 | [
"CONFIRM"
] | [
"table/list"
] | jfkf0226 | train | 588 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAakCAAAAACXAmxUAAEAAElEQVR4nOzd67qqKhSAYdrPui+ZVwZdmXRl7h+eQAaI5oHqe3/UWsphoM4kG9mjUwAAAHX47+4AAAAARkxMAABANZiYAACAajAxAQAA1WBiAgAAqsHEBAAAVIOJCQAAqAYTEwAAUA0mJgAAoBpMTAAAQDWYmAAAgGowMQEAANVgYgIAAKrBxAQAAFSDiQkAAKgGExMAAFANJiYAAKAaTEwAAEA1mJgAAIBqMDEBAADVYGICAACqwcQEAABUg4kJAACoBhMTAABQDSY... | {"gt_parses": [{"question" : "what is the executive summary of bladder cancer cases ?", "answer" : "CONFIRM"}]} |
1,353 | Full form of PEM? | 2 | [
"prescription event monitoring"
] | [
"free_text"
] | gmjf0226 | train | 544 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOyda3rkKLOEo87z7UvplRFaWYVWpvMjASHVxWW33ZZ74p1pV0ncElCRQAK6rDDGGGPOyf/9tADGGGPMI6ykjDHGnBYrKWOMMafFSsoYY8xpsZIyxhhzWqykjDHGnBYrKWOMMafFSsoYY8xpsZIyxhhzWqykjDHGnBYrKWOMMafFSuoFBOmnZfgPI9fAT+Py/3kk6Kdl+BkuPmDWGGPMWfFIyhhjzGmxkjLGGHNarKSMMcacFispY4wxp8VKyhhjzGmxkjL... | {"gt_parses": [{"question" : "Full form of PEM?", "answer" : "prescription event monitoring"}]} |
1,354 | what is the name of the request document ? | 2 | [
"PARTIAL CLINICAL HOLD REMOVAL REQUEST DOCUMENT",
"Partial clinical hold removal request document",
"PARTIAL CLINICAL HOLD REMOVAL"
] | [
"table/list",
"layout"
] | jfkf0226 | train | 588 | "iVBORw0KGgoAAAANSUhEUgAACJgAAAakCAAAAACXAmxUAAEAAElEQVR4nOzd67qqKhSAYdrPui+ZVwZdmXRl7h+eQAaI5oHqe3/UWsphoM4kG9mjUwAAAHX47+4AAAAARkxMAABANZiYAACAajAxAQAA1WBiAgAAqsHEBAAAVIOJCQAAqAYTEwAAUA0mJgAAoBpMTAAAQDWYmAAAgGowMQEAANVgYgIAAKrBxAQAAFSDiQkAAKgGExMAAFANJiYAAKAaTEwAAEA1mJgAAIBqMDEBAADVYGICAACqwcQEAABUg4kJAACoBhMTAABQDSY... | {"gt_parses": [{"question" : "what is the name of the request document ?", "answer" : "PARTIAL CLINICAL HOLD REMOVAL REQUEST DOCUMENT"}, {"question" : "what is the name of the request document ?", "answer" : "Partial clinical hold removal request document"}, {"question" : "what is the name of the request document ?", "... |
1,356 | who appointed as the responsible person on this issue ? | 1 | [
"MR. SAITO",
"Mr. Saito"
] | [
"table/list",
"free_text"
] | ymjf0226 | train | 594 | "iVBORw0KGgoAAAANSUhEUgAABqcAAAi/CAAAAABlohfiAAEAAElEQVR4nOyda7akKgxG4109LzkjI45MHJn3h68AAdHSkqr69lrdx+IRAiIBRGhGAgAAAKrlv6cVAAAAADLATgEAAKgZ2CkAAAA1AzsFAACgZmCnAAAA1AzsFAAAgJqBnQIAAFAzsFMAAABqBnYKAABAzcBOAQAAqBnYKQAAADUDOwUAAKBmYKcAAADUDOwUAACAmoGdAgAAUDOwUwCAC+GnFQDfB+wUAOBCzNMKgO+jwXm+AAAAKgbjKQAAADUDOwUAAKBmYKcAAAD... | {"gt_parses": [{"question" : "who appointed as the responsible person on this issue ?", "answer" : "MR. SAITO"}, {"question" : "who appointed as the responsible person on this issue ?", "answer" : "Mr. Saito"}]} |
1,357 | On the purpose of teleconference, how many topics were to be discussed? | 1 | [
"3",
"3 topics"
] | [
"layout"
] | fsjf0226 | train | 545 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOyda5bjqg6Ft+8680IZmcTILI+M+wOwwY/EqUoqrur9rdWdGPMQOIUMCDEkEEIIIdfkf58WgBBCCDmCSooQQshloZIihBByWaikCCGEXBYqKUIIIZeFSooQQshloZIihBByWaikCCGEXBYqKUIIIZeFSooQQshloZIihBByWaikCCGEXBYqKUIIIZeFSooQQshloZIihBByWaikCCGEXBYqKUIIIZeFSooQQshloZIihBByWaikCCGEXBYqKUIIIZeFSoo... | {"gt_parses": [{"question" : "On the purpose of teleconference, how many topics were to be discussed?", "answer" : "3"}, {"question" : "On the purpose of teleconference, how many topics were to be discussed?", "answer" : "3 topics"}]} |
1,358 | basically by whom the current action plan was approved ? | 1 | [
"CEO"
] | [
"table/list",
"free_text"
] | ymjf0226 | train | 594 | "iVBORw0KGgoAAAANSUhEUgAABqcAAAi/CAAAAABlohfiAAEAAElEQVR4nOyda7akKgxG4109LzkjI45MHJn3h68AAdHSkqr69lrdx+IRAiIBRGhGAgAAAKrlv6cVAAAAADLATgEAAKgZ2CkAAAA1AzsFAACgZmCnAAAA1AzsFAAAgJqBnQIAAFAzsFMAAABqBnYKAABAzcBOAQAAqBnYKQAAADUDOwUAAKBmYKcAAADUDOwUAACAmoGdAgAAUDOwUwCAC+GnFQDfB+wUAOBCzNMKgO+jwXm+AAAAKgbjKQAAADUDOwUAAKBmYKcAAAD... | {"gt_parses": [{"question" : "basically by whom the current action plan was approved ?", "answer" : "CEO"}]} |
1,359 | What is the date mentioned at the bottom? | 1 | [
"09/18/12"
] | [
"layout"
] | fsjf0226 | train | 545 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOyda5bjqg6Ft+8680IZmcTILI+M+wOwwY/EqUoqrur9rdWdGPMQOIUMCDEkEEIIIdfkf58WgBBCCDmCSooQQshloZIihBByWaikCCGEXBYqKUIIIZeFSooQQshloZIihBByWaikCCGEXBYqKUIIIZeFSooQQshloZIihBByWaikCCGEXBYqKUIIIZeFSooQQshloZIihBByWaikCCGEXBYqKUIIIZeFSooQQshloZIihBByWaikCCGEXBYqKUIIIZeFSoo... | {"gt_parses": [{"question" : "What is the date mentioned at the bottom?", "answer" : "09/18/12"}]} |
1,360 | in which month and date it was reported to CEO ? | 1 | [
"AUGUST 6",
"August 6"
] | [
"table/list",
"free_text"
] | ymjf0226 | train | 594 | "iVBORw0KGgoAAAANSUhEUgAABqcAAAi/CAAAAABlohfiAAEAAElEQVR4nOyda7akKgxG4109LzkjI45MHJn3h68AAdHSkqr69lrdx+IRAiIBRGhGAgAAAKrlv6cVAAAAADLATgEAAKgZ2CkAAAA1AzsFAACgZmCnAAAA1AzsFAAAgJqBnQIAAFAzsFMAAABqBnYKAABAzcBOAQAAqBnYKQAAADUDOwUAAKBmYKcAAADUDOwUAACAmoGdAgAAUDOwUwCAC+GnFQDfB+wUAOBCzNMKgO+jwXm+AAAAKgbjKQAAADUDOwUAAKBmYKcAAAD... | {"gt_parses": [{"question" : "in which month and date it was reported to CEO ?", "answer" : "AUGUST 6"}, {"question" : "in which month and date it was reported to CEO ?", "answer" : "August 6"}]} |
1,361 | What is the heading of this document, given at the top? | 5 | [
"Avandamet Uptake"
] | [
"layout"
] | ynjf0226 | train | 596 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbJCAAAAADMqhvuAAEAAElEQVR4nOyda5rrqA5Ft+/X80IZmcTILEbm+wNsgx9Jqk4eVLLX6U4lPGXHMbIQYphACCGEENIJ/3u3AIQQQgghC9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/... | {"gt_parses": [{"question" : "What is the heading of this document, given at the top?", "answer" : "Avandamet Uptake"}]} |
1,362 | What are shown on the x-axis? | 5 | [
"FULL MONTHS POST LAUNCH",
"Full Months Post Launch"
] | [
"figure/diagram",
"layout"
] | ynjf0226 | train | 596 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbJCAAAAADMqhvuAAEAAElEQVR4nOyda5rrqA5Ft+/X80IZmcTILEbm+wNsgx9Jqk4eVLLX6U4lPGXHMbIQYphACCGEENIJ/3u3AIQQQgghC9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/... | {"gt_parses": [{"question" : "What are shown on the x-axis?", "answer" : "FULL MONTHS POST LAUNCH"}, {"question" : "What are shown on the x-axis?", "answer" : "Full Months Post Launch"}]} |
1,363 | what has to be reported to CEO on August 20 (japan time) ? | 1 | [
"AN OUTLINE OF THE FDA RESPONSE",
"an outline of the FDA response"
] | [
"table/list",
"free_text"
] | ymjf0226 | train | 594 | "iVBORw0KGgoAAAANSUhEUgAABqcAAAi/CAAAAABlohfiAAEAAElEQVR4nOyda7akKgxG4109LzkjI45MHJn3h68AAdHSkqr69lrdx+IRAiIBRGhGAgAAAKrlv6cVAAAAADLATgEAAKgZ2CkAAAA1AzsFAACgZmCnAAAA1AzsFAAAgJqBnQIAAFAzsFMAAABqBnYKAABAzcBOAQAAqBnYKQAAADUDOwUAAKBmYKcAAADUDOwUAACAmoGdAgAAUDOwUwCAC+GnFQDfB+wUAOBCzNMKgO+jwXm+AAAAKgbjKQAAADUDOwUAAKBmYKcAAAD... | {"gt_parses": [{"question" : "what has to be reported to CEO on August 20 (japan time) ?", "answer" : "AN OUTLINE OF THE FDA RESPONSE"}, {"question" : "what has to be reported to CEO on August 20 (japan time) ?", "answer" : "an outline of the FDA response"}]} |
1,364 | What is the percentage of Avandamet scripts from Actos mentioned? | 5 | [
"36%",
"36"
] | [
"figure/diagram",
"layout"
] | ynjf0226 | train | 596 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbJCAAAAADMqhvuAAEAAElEQVR4nOyda5rrqA5Ft+/X80IZmcTILEbm+wNsgx9Jqk4eVLLX6U4lPGXHMbIQYphACCGEENIJ/3u3AIQQQgghC9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/... | {"gt_parses": [{"question" : "What is the percentage of Avandamet scripts from Actos mentioned?", "answer" : "36%"}, {"question" : "What is the percentage of Avandamet scripts from Actos mentioned?", "answer" : "36"}]} |
1,365 | what is the name of the policy on Actos issue ? | 1 | [
"TAKEDA BASIC POLICY",
"Takeda basic policy"
] | [
"layout"
] | ymjf0226 | train | 594 | "iVBORw0KGgoAAAANSUhEUgAABqcAAAi/CAAAAABlohfiAAEAAElEQVR4nOyda7akKgxG4109LzkjI45MHJn3h68AAdHSkqr69lrdx+IRAiIBRGhGAgAAAKrlv6cVAAAAADLATgEAAKgZ2CkAAAA1AzsFAACgZmCnAAAA1AzsFAAAgJqBnQIAAFAzsFMAAABqBnYKAABAzcBOAQAAqBnYKQAAADUDOwUAAKBmYKcAAADUDOwUAACAmoGdAgAAUDOwUwCAC+GnFQDfB+wUAOBCzNMKgO+jwXm+AAAAKgbjKQAAADUDOwUAAKBmYKcAAAD... | {"gt_parses": [{"question" : "what is the name of the policy on Actos issue ?", "answer" : "TAKEDA BASIC POLICY"}, {"question" : "what is the name of the policy on Actos issue ?", "answer" : "Takeda basic policy"}]} |
1,366 | What is on the horizonal axis of the graph? | 5 | [
"Full Months Post Launch"
] | [
"figure/diagram"
] | ynjf0226 | train | 596 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbJCAAAAADMqhvuAAEAAElEQVR4nOyda5rrqA5Ft+/X80IZmcTILEbm+wNsgx9Jqk4eVLLX6U4lPGXHMbIQYphACCGEENIJ/3u3AIQQQgghC9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/UTAghhBDSD9RMCCGEENIP1EwIIYQQ0g/... | {"gt_parses": [{"question" : "What is on the horizonal axis of the graph?", "answer" : "Full Months Post Launch"}]} |
1,367 | Heading of the document? | 7 | [
"LINK BETWEEN IR AND CVD",
"Link between IR and CVD"
] | [
"layout"
] | ynjf0226 | train | 597 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbKCAAAAABKPmlAAAEAAElEQVR4nOyda5rrqA5Ft+/X80I1MomRIY+M+wNsgx+JU5VUXCd7dZ+KY/OQHwFZCDFkEEIIIYRchP+9WwBCCCGEkBlqJoQQQgi5DtRMCCGEEHIdqJkQQggh5DpQMyGEEELIdaBmQgghhJDrQM2EEEIIIdeBmgkhhBBCrgM1E0IIIYRcB2omhBBCCLkO1EwIIYQQch2omRBCCCHkOlAzIYQQQsh1oGZCCCGEkOtAzYQQQggh14GaCSGEEEKuAzUTQgghhFwHaiaEEEI... | {"gt_parses": [{"question" : "Heading of the document?", "answer" : "LINK BETWEEN IR AND CVD"}, {"question" : "Heading of the document?", "answer" : "Link between IR and CVD"}]} |
1,369 | who is the chief leader ? | 2 | [
"MR. K SAITO",
"Mr.K Saito"
] | [
"table/list"
] | ymjf0226 | train | 598 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAi9CAAAAAAsn2bUAAD9LklEQVR4nOydabqsKAyGYz93X3JWRlyZcWX2D6cwKc5U1ff20/coQghUFTGMVU8AAABAofz3tgIAAABAElgpAAAA5QIrBQAAoFxgpQAAAJQLrBQAAIBygZUCAABQLrBSAAAAygVWCgAAQLnASgEAACgXWCkAAADlAisFAACgXGClAAAAlAusFAAAgHKBlQLgKfhtBQD4QCqc3AE+CTFvawAAeBRYKQAAAOWCHj8AAADlAisFAAAgH344P/T4AQAAKBf4UgAAAMoFVup... | {"gt_parses": [{"question" : "who is the chief leader ?", "answer" : "MR. K SAITO"}, {"question" : "who is the chief leader ?", "answer" : "Mr.K Saito"}]} |
1,370 | What is the percentage of Nondiabetic patients with prior MI? | 7 | [
"18.8%",
"18.8"
] | [
"figure/diagram"
] | ynjf0226 | train | 597 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbKCAAAAABKPmlAAAEAAElEQVR4nOyda5rrqA5Ft+/X80I1MomRIY+M+wNsgx+JU5VUXCd7dZ+KY/OQHwFZCDFkEEIIIYRchP+9WwBCCCGEkBlqJoQQQgi5DtRMCCGEEHIdqJkQQggh5DpQMyGEEELIdaBmQgghhJDrQM2EEEIIIdeBmgkhhBBCrgM1E0IIIYRcB2omhBBCCLkO1EwIIYQQch2omRBCCCHkOlAzIYQQQsh1oGZCCCGEkOtAzYQQQggh14GaCSGEEEKuAzUTQgghhFwHaiaEEEI... | {"gt_parses": [{"question" : "What is the percentage of Nondiabetic patients with prior MI?", "answer" : "18.8%"}, {"question" : "What is the percentage of Nondiabetic patients with prior MI?", "answer" : "18.8"}]} |
1,371 | who is the responsible person for TPNA ? | 2 | [
"Dr. C Thom"
] | [
"table/list"
] | ymjf0226 | train | 598 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAi9CAAAAAAsn2bUAAD9LklEQVR4nOydabqsKAyGYz93X3JWRlyZcWX2D6cwKc5U1ff20/coQghUFTGMVU8AAABAofz3tgIAAABAElgpAAAA5QIrBQAAoFxgpQAAAJQLrBQAAIBygZUCAABQLrBSAAAAygVWCgAAQLnASgEAACgXWCkAAADlAisFAACgXGClAAAAlAusFAAAgHKBlQLgKfhtBQD4QCqc3AE+CTFvawAAeBRYKQAAAOWCHj8AAADlAisFAAAgH344P/T4AQAAKBf4UgAAAMoFVup... | {"gt_parses": [{"question" : "who is the responsible person for TPNA ?", "answer" : "Dr. C Thom"}]} |
1,373 | what is the name of the organization ? | 2 | [
"ACTOS ISSUE ORGANIZATION",
"Actos issue organization"
] | [
"layout"
] | ymjf0226 | train | 598 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAi9CAAAAAAsn2bUAAD9LklEQVR4nOydabqsKAyGYz93X3JWRlyZcWX2D6cwKc5U1ff20/coQghUFTGMVU8AAABAofz3tgIAAABAElgpAAAA5QIrBQAAoFxgpQAAAJQLrBQAAIBygZUCAABQLrBSAAAAygVWCgAAQLnASgEAACgXWCkAAADlAisFAACgXGClAAAAlAusFAAAgHKBlQLgKfhtBQD4QCqc3AE+CTFvawAAeBRYKQAAAOWCHj8AAADlAisFAAAgH344P/T4AQAAKBf4UgAAAMoFVup... | {"gt_parses": [{"question" : "what is the name of the organization ?", "answer" : "ACTOS ISSUE ORGANIZATION"}, {"question" : "what is the name of the organization ?", "answer" : "Actos issue organization"}]} |
1,374 | who is the responsible person of TCI ? | 2 | [
"MR. K SAITO"
] | [
"table/list"
] | ymjf0226 | train | 598 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAi9CAAAAAAsn2bUAAD9LklEQVR4nOydabqsKAyGYz93X3JWRlyZcWX2D6cwKc5U1ff20/coQghUFTGMVU8AAABAofz3tgIAAABAElgpAAAA5QIrBQAAoFxgpQAAAJQLrBQAAIBygZUCAABQLrBSAAAAygVWCgAAQLnASgEAACgXWCkAAADlAisFAACgXGClAAAAlAusFAAAgHKBlQLgKfhtBQD4QCqc3AE+CTFvawAAeBRYKQAAAOWCHj8AAADlAisFAAAgH344P/T4AQAAKBf4UgAAAMoFVup... | {"gt_parses": [{"question" : "who is the responsible person of TCI ?", "answer" : "MR. K SAITO"}]} |
1,375 | What is the Handwritten sentence on the top? | 1 | [
"Row-Contract (as of 7/19/99)"
] | [
"handwritten",
"layout"
] | trjf0226 | train | 600 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAADty0lEQVR4nOzda7aqvBKF4ckZX7/IblmKllm0jPODW7gpKkpcvM8Yey/lEkpUypAQikYAAOTpf2cHAADAFpIUACBbJCkAQLZIUgCAbJGkAADZIkkBALJFkgIAZIskBQDIFkkKAJAtkhQAIFskKQBAtkhSAIBskaQAANkiSQEAskWSAgBkiyQFAMgWSQoAkC2SFAAgWyQpAEC2SFIAgGyRpAAA2SJJAQCyRZICAGSLJAUAyBZJCgCQLZIUACBbJCkAQLZIUgCAbJGkAAD... | {"gt_parses": [{"question" : "What is the Handwritten sentence on the top?", "answer" : "Row-Contract (as of 7/19/99)"}]} |
1,376 | What is the date mentioned? | 1 | [
"JULY 19, 1999",
"July 19, 1999"
] | [
"layout"
] | trjf0226 | train | 600 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAADty0lEQVR4nOzda7aqvBKF4ckZX7/IblmKllm0jPODW7gpKkpcvM8Yey/lEkpUypAQikYAAOTpf2cHAADAFpIUACBbJCkAQLZIUgCAbJGkAADZIkkBALJFkgIAZIskBQDIFkkKAJAtkhQAIFskKQBAtkhSAIBskaQAANkiSQEAskWSAgBkiyQFAMgWSQoAkC2SFAAgWyQpAEC2SFIAgGyRpAAA2SJJAQCyRZICAGSLJAUAyBZJCgCQLZIUACBbJCkAQLZIUgCAbJGkAAD... | {"gt_parses": [{"question" : "What is the date mentioned?", "answer" : "JULY 19, 1999"}, {"question" : "What is the date mentioned?", "answer" : "July 19, 1999"}]} |
1,377 | who is the first contact person of EuR&D ? | 2 | [
"DR. P COLLETT",
"Dr. P Collett"
] | [
"table/list"
] | ymjf0226 | train | 598 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAi9CAAAAAAsn2bUAAD9LklEQVR4nOydabqsKAyGYz93X3JWRlyZcWX2D6cwKc5U1ff20/coQghUFTGMVU8AAABAofz3tgIAAABAElgpAAAA5QIrBQAAoFxgpQAAAJQLrBQAAIBygZUCAABQLrBSAAAAygVWCgAAQLnASgEAACgXWCkAAADlAisFAACgXGClAAAAlAusFAAAgHKBlQLgKfhtBQD4QCqc3AE+CTFvawAAeBRYKQAAAOWCHj8AAADlAisFAAAgH344P/T4AQAAKBf4UgAAAMoFVup... | {"gt_parses": [{"question" : "who is the first contact person of EuR&D ?", "answer" : "DR. P COLLETT"}, {"question" : "who is the first contact person of EuR&D ?", "answer" : "Dr. P Collett"}]} |
1,378 | With whom is the discussion being held? | 1 | [
"JIM HARPER",
"Jim Harper"
] | [
"layout"
] | trjf0226 | train | 600 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAADty0lEQVR4nOzda7aqvBKF4ckZX7/IblmKllm0jPODW7gpKkpcvM8Yey/lEkpUypAQikYAAOTpf2cHAADAFpIUACBbJCkAQLZIUgCAbJGkAADZIkkBALJFkgIAZIskBQDIFkkKAJAtkhQAIFskKQBAtkhSAIBskaQAANkiSQEAskWSAgBkiyQFAMgWSQoAkC2SFAAgWyQpAEC2SFIAgGyRpAAA2SJJAQCyRZICAGSLJAUAyBZJCgCQLZIUACBbJCkAQLZIUgCAbJGkAAD... | {"gt_parses": [{"question" : "With whom is the discussion being held?", "answer" : "JIM HARPER"}, {"question" : "With whom is the discussion being held?", "answer" : "Jim Harper"}]} |
1,380 | who is the responsible person for EuR&D ? | 2 | [
"DR. D ECKLAND",
"Dr. D Eckland"
] | [
"table/list"
] | ymjf0226 | train | 598 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAi9CAAAAAAsn2bUAAD9LklEQVR4nOydabqsKAyGYz93X3JWRlyZcWX2D6cwKc5U1ff20/coQghUFTGMVU8AAABAofz3tgIAAABAElgpAAAA5QIrBQAAoFxgpQAAAJQLrBQAAIBygZUCAABQLrBSAAAAygVWCgAAQLnASgEAACgXWCkAAADlAisFAACgXGClAAAAlAusFAAAgHKBlQLgKfhtBQD4QCqc3AE+CTFvawAAeBRYKQAAAOWCHj8AAADlAisFAAAgH344P/T4AQAAKBf4UgAAAMoFVup... | {"gt_parses": [{"question" : "who is the responsible person for EuR&D ?", "answer" : "DR. D ECKLAND"}, {"question" : "who is the responsible person for EuR&D ?", "answer" : "Dr. D Eckland"}]} |
1,381 | What is the date of randomisation? | 3 | [
"05-11-01",
"05/11/01"
] | [
"form"
] | rljf0226 | train | 602 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOyda5qrOK+FV87zzUvaI5MYGfLIfH7INoYkVanUJVTXert3kYDvEGRZsn2pIIQQQs7J/726AIQQQsg9KKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQ... | {"gt_parses": [{"question" : "What is the date of randomisation?", "answer" : "05-11-01"}, {"question" : "What is the date of randomisation?", "answer" : "05/11/01"}]} |
1,382 | who is the first contact person of TPNA ? | 2 | [
"MS. M RAMSTACK, MS. J HASKINS",
"Ms. M Ramstack ,Ms. J Haskins"
] | [
"table/list"
] | ymjf0226 | train | 598 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAi9CAAAAAAsn2bUAAD9LklEQVR4nOydabqsKAyGYz93X3JWRlyZcWX2D6cwKc5U1ff20/coQghUFTGMVU8AAABAofz3tgIAAABAElgpAAAA5QIrBQAAoFxgpQAAAJQLrBQAAIBygZUCAABQLrBSAAAAygVWCgAAQLnASgEAACgXWCkAAADlAisFAACgXGClAAAAlAusFAAAgHKBlQLgKfhtBQD4QCqc3AE+CTFvawAAeBRYKQAAAOWCHj8AAADlAisFAAAgH344P/T4AQAAKBf4UgAAAMoFVup... | {"gt_parses": [{"question" : "who is the first contact person of TPNA ?", "answer" : "MS. M RAMSTACK, MS. J HASKINS"}, {"question" : "who is the first contact person of TPNA ?", "answer" : "Ms. M Ramstack ,Ms. J Haskins"}]} |
1,383 | What is the patient number? | 3 | [
"014"
] | [
"form"
] | rljf0226 | train | 602 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOyda5qrOK+FV87zzUvaI5MYGfLIfH7INoYkVanUJVTXert3kYDvEGRZsn2pIIQQQs7J/726AIQQQsg9KKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQ... | {"gt_parses": [{"question" : "What is the patient number?", "answer" : "014"}]} |
1,384 | What is the Centre number? | 3 | [
"49013"
] | [
"form"
] | rljf0226 | train | 602 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOyda5qrOK+FV87zzUvaI5MYGfLIfH7INoYkVanUJVTXert3kYDvEGRZsn2pIIQQQs7J/726AIQQQsg9KKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQ... | {"gt_parses": [{"question" : "What is the Centre number?", "answer" : "49013"}]} |
1,385 | who is the first contact person of TCI ? | 2 | [
"MR. M MIYAZAKI",
"Mr. M Miyazaki"
] | [
"table/list"
] | ymjf0226 | train | 598 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAi9CAAAAAAsn2bUAAD9LklEQVR4nOydabqsKAyGYz93X3JWRlyZcWX2D6cwKc5U1ff20/coQghUFTGMVU8AAABAofz3tgIAAABAElgpAAAA5QIrBQAAoFxgpQAAAJQLrBQAAIBygZUCAABQLrBSAAAAygVWCgAAQLnASgEAACgXWCkAAADlAisFAACgXGClAAAAlAusFAAAgHKBlQLgKfhtBQD4QCqc3AE+CTFvawAAeBRYKQAAAOWCHj8AAADlAisFAAAgH344P/T4AQAAKBf4UgAAAMoFVup... | {"gt_parses": [{"question" : "who is the first contact person of TCI ?", "answer" : "MR. M MIYAZAKI"}, {"question" : "who is the first contact person of TCI ?", "answer" : "Mr. M Miyazaki"}]} |
1,386 | What is the Reference mentioned here? | 3 | [
"135037-HRT-11",
"135037-hrt-11"
] | [
"form"
] | rljf0226 | train | 602 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOyda5qrOK+FV87zzUvaI5MYGfLIfH7INoYkVanUJVTXert3kYDvEGRZsn2pIIQQQs7J/726AIQQQsg9KKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQIIYScFgopQgghp4VCihBCyGmhkCKEEHJaKKQ... | {"gt_parses": [{"question" : "What is the Reference mentioned here?", "answer" : "135037-HRT-11"}, {"question" : "What is the Reference mentioned here?", "answer" : "135037-hrt-11"}]} |
1,387 | What is the heading of the table? | 13 | [
"Weight Changes (kg) from Baseline during Double-Blind Clinical Trials with ACTOS"
] | [
"layout"
] | hfkf0226 | train | 604 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAiZCAAAAACwoiH0AAEAAElEQVR4nOxdaXLjOq89/dXbF9Qrg7IyyCvD+4GBIC07ztA3iYNTFUcDCYIURQyEyD+KRqPRaDS+Kf731Qw0Go1Go3ETLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBrfFy2lGo1Go/F90VKq0Wg0Gt8XLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBrfFy2lGo1Go/F90VKq0Wg0Gt8XLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBr... | {"gt_parses": [{"question" : "What is the heading of the table?", "answer" : "Weight Changes (kg) from Baseline during Double-Blind Clinical Trials with ACTOS"}]} |
1,388 | what is the total number of drug claims under the title of "summary of litigation risk in the ous territories"? | 4 | [
"5"
] | [
"table/list"
] | trjf0226 | train | 575 | "iVBORw0KGgoAAAANSUhEUgAABqcAAAi+CAAAAACu/sRHAAEAAElEQVR4nOzdWZqrOhKF0U19d16ER6bQyByMjHqQAIHtTDsbWz75r6p70qYRckeglmEWAADd+t+rMwAAwAeIUwCAnhGnAAA9I04BAHpGnAIA9Iw4BQDoGXEKANAz4hQAoGfEKQBAz4hTAICeEacAAD0jTgEAekacAgD0jDgFAOgZcQoA0DPiFACgZ8QpAEDPiFMAgJ4RpwAAPSNOAQB6RpwCAPSMOAUA6BlxCgDQM+IUAKBnxCkAQM+IUwCAnhGnAAA9I04BAHpGnAI... | {"gt_parses": [{"question" : "what is the total number of drug claims under the title of "summary of litigation risk in the ous territories"?", "answer" : "5"}]} |
1,389 | what are secondary endpoints ? | 7 | [
"CARDIOVASCULAR MORTALITY",
"cardiovascular mortality"
] | [
"form"
] | fzjf0226 | train | 606 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbJCAAAAADMqhvuAAEAAElEQVR4nOyd7XqsKhKFl/Oc+4JcGeWVWV6Z8wOQAsG2O53EZK935uwoH0WBtpRQ4LSBEEIIIeQm/O+nFSCEEEII2aFlQgghhJD7QMuEEEIIIfeBlgkhhBBC7gMtE0IIIYTcB1omhBBCCLkPtEwIIYQQch9omRBCCCHkPtAyIYQQQsh9oGVCCCGEkPtAy4QQQggh94GWCSGEEELuAy0TQgghhNwHWiaEEEIIuQ+0TAghhBByH2iZEEIIIeQ+0DIhhBBCyH2gZUIIIYS... | {"gt_parses": [{"question" : "what are secondary endpoints ?", "answer" : "CARDIOVASCULAR MORTALITY"}, {"question" : "what are secondary endpoints ?", "answer" : "cardiovascular mortality"}]} |
1,390 | what is the title of this page? | 4 | [
"OBJECTIVES AND METHODOLOGY",
"objectives and methodology"
] | [
"layout"
] | rnjf0226 | train | 608 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOyda3rsqK6GvzrPnpfIyCSPDDEyzg+Jm8uucm4r1Yne7hWXbS4CYwNCwK0iCIIgCF6T//tpAYIgCILgjKikgiAIgpclKqkgCILgZYlKKgiCIHhZopIKgiAIXpaopIIgCIKXJSqpIAiC4GWJSioIgiB4WaKSCoIgCF6WqKSCIAiClyUqqSAIguBliUoqCIIgeFmikgqCIAhelqikgiAIgpclKqkgCILgZYlKKgiCIHhZopIKgiAIXpaopIIgCIKXJSqpIAi... | {"gt_parses": [{"question" : "what is the title of this page?", "answer" : "OBJECTIVES AND METHODOLOGY"}, {"question" : "what is the title of this page?", "answer" : "objectives and methodology"}]} |
1,391 | What is the number of patients ? | 7 | [
"5,000"
] | [
"form"
] | fzjf0226 | train | 606 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbJCAAAAADMqhvuAAEAAElEQVR4nOyd7XqsKhKFl/Oc+4JcGeWVWV6Z8wOQAsG2O53EZK935uwoH0WBtpRQ4LSBEEIIIeQm/O+nFSCEEEII2aFlQgghhJD7QMuEEEIIIfeBlgkhhBBC7gMtE0IIIYTcB1omhBBCCLkPtEwIIYQQch9omRBCCCHkPtAyIYQQQsh9oGVCCCGEkPtAy4QQQggh94GWCSGEEELuAy0TQgghhNwHWiaEEEIIuQ+0TAghhBByH2iZEEIIIeQ+0DIhhBBCyH2gZUIIIYS... | {"gt_parses": [{"question" : "What is the number of patients ?", "answer" : "5,000"}]} |
1,392 | What is "FPV" ? | 7 | [
"JUNE 2001",
"June 2001"
] | [
"form"
] | fzjf0226 | train | 606 | "iVBORw0KGgoAAAANSUhEUgAACJkAAAbJCAAAAADMqhvuAAEAAElEQVR4nOyd7XqsKhKFl/Oc+4JcGeWVWV6Z8wOQAsG2O53EZK935uwoH0WBtpRQ4LSBEEIIIeQm/O+nFSCEEEII2aFlQgghhJD7QMuEEEIIIfeBlgkhhBBC7gMtE0IIIYTcB1omhBBCCLkPtEwIIYQQch9omRBCCCHkPtAyIYQQQsh9oGVCCCGEkPtAy4QQQggh94GWCSGEEELuAy0TQgghhNwHWiaEEEIIuQ+0TAghhBByH2iZEEIIIeQ+0DIhhBBCyH2gZUIIIYS... | {"gt_parses": [{"question" : "What is "FPV" ?", "answer" : "JUNE 2001"}, {"question" : "What is "FPV" ?", "answer" : "June 2001"}]} |
1,393 | What is the ACTOS 15 mg of Monotherapy? | 13 | [
"0.9(-0.5/3.4) N=79",
"0.9(-0.5/3.4) n=79"
] | [
"table/list"
] | hfkf0226 | train | 604 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAiZCAAAAACwoiH0AAEAAElEQVR4nOxdaXLjOq89/dXbF9Qrg7IyyCvD+4GBIC07ztA3iYNTFUcDCYIURQyEyD+KRqPRaDS+Kf731Qw0Go1Go3ETLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBrfFy2lGo1Go/F90VKq0Wg0Gt8XLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBrfFy2lGo1Go/F90VKq0Wg0Gt8XLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBr... | {"gt_parses": [{"question" : "What is the ACTOS 15 mg of Monotherapy?", "answer" : "0.9(-0.5/3.4) N=79"}, {"question" : "What is the ACTOS 15 mg of Monotherapy?", "answer" : "0.9(-0.5/3.4) n=79"}]} |
1,395 | What is the trial duration mentioned? | 13 | [
"16 TO 26 WEEKS",
"16 to 26 weeks"
] | [
"table/list",
"layout"
] | hfkf0226 | train | 604 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAiZCAAAAACwoiH0AAEAAElEQVR4nOxdaXLjOq89/dXbF9Qrg7IyyCvD+4GBIC07ztA3iYNTFUcDCYIURQyEyD+KRqPRaDS+Kf731Qw0Go1Go3ETLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBrfFy2lGo1Go/F90VKq0Wg0Gt8XLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBrfFy2lGo1Go/F90VKq0Wg0Gt8XLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBr... | {"gt_parses": [{"question" : "What is the trial duration mentioned?", "answer" : "16 TO 26 WEEKS"}, {"question" : "What is the trial duration mentioned?", "answer" : "16 to 26 weeks"}]} |
1,396 | what is the name of the form ? | 2 | [
"URGENT DATA ENQUIRY FORM",
"urgent data enquiry form",
"URGENT DATA ENQUIRY"
] | [
"layout"
] | rljf0226 | train | 610 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOydbXrrqBKEy/PcfVFZGc3KUlqZ7o8GfdhOjuMktpLUO3MiSwIESHar6W44zTDGGGOOyX/ProAxxhjzFkcXUoKeXQVjjDHP4uThPmOMMUfl6JoUAtaljDHmr2JNyhhjzGE5vCZljDHm73JcIRX9bzy1FgaIeHYNjDF/Fg/3GWOMOSzH1aSMMcb8eSykzD/QsytgjPnDeLjPGGPMYbEmZW5Dz67An0WOFjR/GWtSxhhjDos1KWOMMYfFQsoYY8xhsZAyxhh... | {"gt_parses": [{"question" : "what is the name of the form ?", "answer" : "URGENT DATA ENQUIRY FORM"}, {"question" : "what is the name of the form ?", "answer" : "urgent data enquiry form"}, {"question" : "what is the name of the form ?", "answer" : "URGENT DATA ENQUIRY"}]} |
1,397 | what is the centre number ? | 2 | [
"49013"
] | [
"form"
] | rljf0226 | train | 610 | "iVBORw0KGgoAAAANSUhEUgAABqQAAAi8CAAAAAAIAd5PAAEAAElEQVR4nOydbXrrqBKEy/PcfVFZGc3KUlqZ7o8GfdhOjuMktpLUO3MiSwIESHar6W44zTDGGGOOyX/ProAxxhjzFkcXUoKeXQVjjDHP4uThPmOMMUfl6JoUAtaljDHmr2JNyhhjzGE5vCZljDHm73JcIRX9bzy1FgaIeHYNjDF/Fg/3GWOMOSzH1aSMMcb8eSykzD/QsytgjPnDeLjPGGPMYbEmZW5Dz67An0WOFjR/GWtSxhhjDos1KWOMMYfFQsoYY8xhsZAyxhh... | {"gt_parses": [{"question" : "what is the centre number ?", "answer" : "49013"}]} |
1,398 | What is the ACTOS 45 mg of Combination Therapy of Insulin? | 13 | [
"4.1 (1.4/6.8) N=338",
"4.1 (1.4/6.8) N=338"
] | [
"table/list"
] | hfkf0226 | train | 604 | "iVBORw0KGgoAAAANSUhEUgAABqUAAAiZCAAAAACwoiH0AAEAAElEQVR4nOxdaXLjOq89/dXbF9Qrg7IyyCvD+4GBIC07ztA3iYNTFUcDCYIURQyEyD+KRqPRaDS+Kf731Qw0Go1Go3ETLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBrfFy2lGo1Go/F90VKq0Wg0Gt8XLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBrfFy2lGo1Go/F90VKq0Wg0Gt8XLaUajUaj8X3RUqrRaDQa3xctpRqNRqPxfdFSqtFoNBr... | {"gt_parses": [{"question" : "What is the ACTOS 45 mg of Combination Therapy of Insulin?", "answer" : "4.1 (1.4/6.8) N=338"}, {"question" : "What is the ACTOS 45 mg of Combination Therapy of Insulin?", "answer" : "4.1 (1.4/6.8) N=338"}]} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.